Table 5

Percentage utilisation of oral generic risperidone versus total risperidone (DDD basis) and percentage reduction in expenditure per defined daily dose for oral generic risperidone versus pre-patent loss prices by the end of the study period in each country
Country Utilisation of generic risperidone, % Price reduction, %
Belgium 52 59
Ireland 14 28
Scotland 98 84
Sweden 96 80

Godman et al.

Godman et al. BMC Medicine 2014 12:98   doi:10.1186/1741-7015-12-98

Open Data